BUY Glenmark Pharmaceuticals — Rajesh Palviya, Axis Securities
byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))7 Aug 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Glenmark Pharma's India-US Growth Story Intact, Says Motilal Oswal, Maintaining 'Buy' — Check Target Price
NewsNdtv-Profit·4 Aug · 6d ago
Glenmark Pharma Q1 profit jumps over 10-fold as India, North America businesses power growth
NewsCnbc-Tv18·31 Jul · 1w ago
Glenmark Pharma Q1 Results: Profit Rises Exponentially To Rs 483 Crore; Revenue Jumps 23%
NewsNdtv-Profit·31 Jul · 1w ago
Glenmark Pharmaceuticals Inc., USA has launched Sugammadex Injection in single-dose vials, available in 200 mg/2mL and 500 mg/5mL strengths.
BSE · Company Update·28 Jul · 2w ago
2 advisors have active short-term BUY calls on this stock
Advisor consensus · adjacent horizon·7 Jul · 1mo ago
Stock Picks Today: Glenmark Pharma, United Spirits, Kansai Nerolac, UPL, Exide And More On Brokerages' Radar
NewsNdtv-Profit·4 Aug · 6d ago
Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·31 Jul · 1w ago
The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026
BSE · Board Meeting·31 Jul · 1w ago
1 other SEBI-registered advisor has an active swing SELL call on this stock, issued in the last 14 days
Advisor consensus · same horizon·7 Aug · 2d ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.